The company had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30gSsks
via IFTTT
0 comments:
Post a Comment